Kornimate/medical-research-clean huggingface dataset:
comparative effects of acbt and diaphragmatic breathing on pulmonary function and sputum diary after cabg

Conditions: Breathing Exercises

Summary: to compare the effects of active cycle of breathing technique and diaphragmatic breathing on pulmonary functions and sputum diary after coronary artery bypass graf

it will be a randomized clinical trial. age of selected subjects will be between 40 to 60 years and data will be collected from intensive care units (icus) and cardiac care units (ccus) of selected hospitals. there will be 2 groups i.e. group a will receive active cycle of breathing technique (acbt) and group b will receive diaphragmatic breathing technique. spirometer will be used to evaluate pulmonary functions and breathless, cough and sputum scale (bcss) will be used to evaluate the improvement in sputum diary of patients. the trial will be completed in two days after patients admitted in the icus/ccus and before and after each session, primary and secondary outcomes will be measured for both groups. after data collection, data will be analyzed using spss version 25

Eligibility criteria:
inclusion criteria: * post-cabg patients * gender: males and females * have speaking, hearing and cognitive ability * on mechanical ventilation for ≤ 24 h after cabg exclusion criteria: * prior history of open heart surgery * prior severe pulmonary/hepatic or renal disease- complications after cabg (cardiogenic shock, bleeding requiring transfusion, acute kidney injury, cardiac temponade and severe hypotension) * life-threatening arrhythmias (ventricular fibrillation, ventricular tachycardia, atrial fibrillation) * on mechanical ventilator for more than 24 h after cabg * pulmonary complications (atelectasis, acute respiratory distress syndrome (ards), diaphragmatic injury)

Keywords: diaphragmatic exercise pulmonary function test
anxiety before non-cardiac surgery in adults

Conditions: Myoma of Uterus; Colon Cancer; Gastric Carcinoma; Prostate Cancer; Femoral Head Necrosis

Summary: adult patients undergoing elective non-cardiac surgery were enrolled. anxiety before the operation was evaluated by the state anxiety inventory (s-ai). logistics regression would be used for identifying the independent factors of preoperative anxiety and prediction model would be established.


Eligibility criteria:
inclusion criteria: 1. patients undergoing elective with general anesthesia surgery (gynecologic oncology, general surgery, orthopedics and urinary); 2. the estimated operation time is more than 2 hours. 3)18≤ age ≤ 80; 4)be able to communicate normally in daily life, without serious hearing and visual impairment; 5)asa:i-ii; 6)sign informed consent and volunteer to participate in this study. exclusion criteria: 1. having a history of brain diseases, such as stroke, epilepsy, psychosis other history of neuropsychiatry. 2. patients with serious diseases of heart, liver, lung, kidney or other organs. 3. having a definite diagnosis of cognitive impairment, such as alzheimer's disease; 4. those who use sedatives before evaluation in this study; 5. drug addicts; 6. alcoholics; 7. pregnant women; 8. participated in other clinical trials as a subject in the past 3 months.
personalized antisense oligonucleotide therapy for a single participant with atn1 gene mutation

Conditions: Dentatorubral-Pallidoluysian Atrophy

Summary: this research project entails delivery of a personalized antisense oligonucleotide (aso) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (drpla) due to a heterozygous pathogenic cag trinucleotide expansion in atn1

this is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (aso) treatment in a single participant with drpla due to a heterozygous pathogenic cag trinucleotide expansion in atn1

Eligibility criteria:
inclusion criteria: * informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s). * ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records. * genetically confirmed dentatorubral-pallidoluysian atrophy (drpla) due to atn1 mutation exclusion criteria: * use of investigational medication within 5 half-lives of the drug at enrolment * participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures.
effect of carum carvi on thyroid hormones and tsh level

Conditions: Thyroid Cancer Patients

Summary: carum carvi has been frequently used in traditional medicine for a variety of disease ranging from dyspepsia to alzheimer's disease.we observed high tsh levels in few patients with thyroid cancer who receiving carum carvi despite being on suppressive dose of levothyroxin. tsh level returned to normal after discontinuation of the carum carvi. this observation led to a pilot study for evaluation of the effect of carum carvi on thyroid function.


Eligibility criteria:
inclusion criteria: * age 18-65 * hypothyroid patients under treatment with levothyroxin * normal euthyroid patients with no goiter exclusion criteria: * pregnancy or lactation * severe lung or gasterointestinal disease * heart failure or renal failure

Keywords: well differentiated thyroid cancer carum carvi normal controls
impact of tamsulosin on voiding patterns following early catheter removal after robot-assisted laparoscopic radical prostatectomy

Conditions: Prostatic Neoplasms, Prostatectomy

Summary: to date, there is a lack of consensus concerning the optimal timing for removal of the urethral catheter, its related complications, the effectiveness in prophylactic drug use to reduce complication, and the patient reported outcomes (quality of life) after robot-assisted laparoscopic prostatectomy (ralp). the purpose of this study is to determine the impact of tamsulosin on voiding patterns following early urethral catheter removal after ralp for prostate cancer.


Eligibility criteria:
inclusion criteria: * patients must have localized or locally advanced prostate cancer * patients must receive robot assisted laparoscopic radical prostatectomy * patients must be able to provide written informed consent exclusion criteria: * patients must not have a history of treatment with alpha blockers within 4 weeks * patients must not have previously undergone transurethral resection, laser therapy, or other surgery of the prostate * patients must not have previously been diagnosed with neurogenic bladder * patients must not have hypersensitivity to trial drug or other alpha-blockers * patients must not have the participation of other clinical trial within the past 3 months
evaluating use of continuous glucose monitors in a short-term 2x2-crossover study

Conditions: Diabetes Type 2; Diabetes Mellitus

Summary: this 5-week, double-blind, placebo-controlled, 2x2 crossover pilot study investigate the potential of collecting robust, real-time clinical study measures of glucose levels using abbott freestyle libre continuous glucose monitoring devices associated with a smartphone application

the goal of this study is to characterize the performance of a continuous glucose monitoring system in medical food studies. the freestyle libre glucose sensors will be used to follow subject's 8-day glucose trajectories over the course of a 5-week, double-blind, placebo-controlled, 2x2 crossover, medical-food experiment. the medical food has been designed to increase butyrate production and promote the health of the colonic mucin layer.

Eligibility criteria:
inclusion criteria: * age: 18 to 75 years of age * if female, must meet all the following criteria: * not pregnant or breastfeeding * if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods \[male condom with spermicide, with or without cervical cap or diaphragm\], implants, injectable or oral contraceptives \[must have been using for at least the last 3 months\], some intrauterine contraceptive devices, tubal ligation, or in an established relationship with a vasectomized partner) during the entire duration of the study * must be able to read, understand, and sign the informed consent forms (icf) and, when applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 \[hipaa\] legislation as modified in 2013) * must be able to communicate with the investigator, and understand and comply with protocol requirements * must be able to wear a cg patch and perform a scan no less than once every 8 hours for the duration of the sensor periods. exclusion criteria: * subjects who plan to use antibiotic, antifungal, antiparasitic, or antiviral treatment during the study * subjects using a proton pump inhibitor must be on a stable dose that will be maintained throughout the study period * subjects who plan to travel outside the united states during the projected study period * subjects who have received an experimental drug within 30 days prior to study entry * subjects with known milk, peanut, or tree nut allergies * subjects who have been diagnosed with a sexually transmitted disease including, but not limited to, hiv, syphilis, herpes, gonorrhea, hepatitis a, hepatitis b, and hepatitis c * history of any surgery on the gastrointestinal tract except appendectomy and cholecystectomy * subjects with any condition that the investigator deems as a sound reason for disqualification from enrollment into the study
intracellular counter-regulatory mechanisms following low blood glucose

Conditions: Diabetes Mellitus Type I; Hypoglycemia

Summary: diabetes mellitus type i (dmi) is characterized by lack of endogenous insulin and these patients are 100% dependent on insulin substitution to survive. diabetes mellitus type ii (dmii) is characterized by reduced insulin sensitivity and sometimes also reduced insulin production, thus patients with dmii might also be dependent on insulin substitution. insulin is produced in- and secreted from the pancreas when blood glucose concentration rises during- and after a meal. insulin increases cellular uptake of glucose leading to lower blood glucose concentration. substitution with insulin is/can be necessary in dm, but at the same time it induces the risk of hypoglycemia. this makes treatment with insulin a balancing act between hyper- and hypoglycemia. a hypoglycemic episode is a dreaded consequence of insulin overdosing, and also a very frequent reason for hospital admission in patients with dm. examples of hypoglycemic symptoms may be; shaking, a sense of hunger, sweating, irritability progressing to lack of relevant cerebral responses and eventually coma, convulsions and possibly death. people with diabetes lose the ability to sense of low blood glucose with time, because of a lack of appropriate counter-regulatory responses, hereby increasing the risk of severe hypoglycemia. understanding normal physiologic counter regulatory mechanisms during hypoglycemia is of major importance to patients with dm and has the potential to change medical treatment in diabetes, to reduce the risk of hypoglycemia. hypothesis: hypoglycemia counteracts insulin signaling via hormone-dependent intracellular counter-regulatory mechanisms, involving phosphorylation of specific signaling proteins. aim: to define counter-regulatory mechanisms in muscle- and fat tissue during hypoglycemia, and to investigate the effect of insulin on lipid metabolism in healthy- and type i diabetic subjects.


Eligibility criteria:
* bmi \> 19 and \< 26 * written consent exclusion criteria: * epilepsy * cardiac arrythmia * ischemic heart disease * other medical illness

Keywords: diabetes mellitus type i hypoglycemia counter-regulatory mechanisms
brain metastases study: radiotherapy fractionation schemes in the treatment of brain metastases

Conditions: Neoplasm Metastasis; Brain Neoplasms

Summary: this is a comparison of radiotherapy fractionation schemes for brain metastasis.

untreated brain metastases are usually fatal within a few weeks. the standard treatment for brain metastases is whole brain irradiation. this results on average in an increase in survival by 2 to 4 times compared to withholding irradiation. the majority of patients experience improvement in the level of functioning as a result of irradiation. none-the-less approximately half of patients die because of progression of the brain metastases and their quality of life is often dominated by the effects of brain metastases. various different dosages of radiation have been assessed and we wish to further investigate this by comparing a less intense schema with a more intense schema. both of these fall within the range of published experience but have not been directly compared. the more intense schema may have more effect on the tumour but previous variations of dose intensity have not shown significant differences in survival. differences in control of the metastases in the brain have been suggested but there have been no good comparisons of quality of life. obviously when survival is measured on average in only 3 to 6 months, this is an important parameter for comparison. comparisons: stratification is by diagnosis either excision or biopsy/clinical. patients will be randomised to receive either 40gy 20#bd or 20gy 4#daily.

Eligibility criteria:
inclusion criteria: * ecog performance status 0 - 2. * brain metastasis. brain biopsy not obligatory if known previous malignancy and multiple lesions typical on computed tomography (ct) scan of brain. solitary lesions, if suitably located, should be biopsied and preferably excised. * extracranial disease stable or absent (i.e. no progression over 2 months) or concurrent presentation of brain metastasis and extracranial disease at time of initial cancer diagnosis. * able to consent * life expectancy exceeds 2 months

Keywords: radiotherapy qualify of life neoplasm metastasis of the brain
study of the pathogenesis and molecular mechanism of "yure" in internal intractable diseases

Conditions: Stroke

Summary: the purpose of this study is to determine whether the chinese herbs formula is effective in the treatment of hemorrhagic stroke and to find out chinese pathogeny and pathogenesis in the disease.

blood stasis and blood heat are two pathogens in the theory system of chinese medicine, which can cause many diseases independently. but in internal intractable diseases, such as viral hepatitis, stroke, and epidemic hemorrhagic fever, blood stasis and blood heat always accompany with each other. so the hypothesis is raised that blood stasis with heat (yure) is a compound pathogen and key pathogenesis in internal intractable diseases. this study was aimed to verify the role that the compound pathogen played in hemorrhagic stroke and to observe the progress of the key pathogenesis. a randomized and controlled trial would be conducted in five hospitals, where 300 hospitalized patients with hemorrhagic stroke in the acute phase would receive different intervention with basic modern medicine treatment or chinese herbs formula combined with the former. the chinese herbs formula, which was designed under the guidance of the theory system of chinese medicine, was supposed to cool blood heat and dissolve blood stasis. clinical efficacy and safety would be evaluated after the 21-days intervention.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hemorrhagic stroke * hospitalized in 48 hours after hemorrhagic stroke happens exclusion criteria: * subarachnoid hemorrhage * intracranial hemorrhage caused by tumor, trauma or blood diseases

Keywords: hemorrhagic stroke chinese medicine pathogenesis yure
effects of a personalized standardized rehabilitation program in systemic sclerosis

Conditions: Systemic Scleroderma

Summary: systemic sclerosis (ssc) is a connective-tissue disease characterized by excessive collagen deposition, vascular hyper-reactivity and obliterative microvascular phenomena leading to disability, handicap, and worsening of quality of life. pharmacological treatments are mainly used for vascular involvement. to date, no pharmacological treatment have been shown to be effective for the fibrosis leading to skin, tendon, and joint disability. our hypothesis is that rehabilitation could be an interesting non pharmacological treatment in order to decrease the handicap of ssc patients. our objective is to evaluate the effect of a personalized standardized rehabilitation program on the quality of life of ssc patients in a multicentric randomized controlled trial. this trial will compare a personalized standardized rehabilitation program to the usual non pharmacological treatment. the primary outcome measure will be the haq di (health assessment questionnaire disability index). a zelen design will be used for this study.


Eligibility criteria:
inclusion criteria: * men or women aged from 18 years or more, with diagnostic of ssc considering the acr and/or leroy and medsger's criteria. * haq greater than or equal to 0.5 * a perception of limitation of mouth opening and/or at least one limitation in range of motion due to illness * good understanding of the french language exclusion criteria : * associated chronic handicap diseases (stroke, multiple sclerosis, amyotrophic lateral sclerosis, parkinson's disease, amputated ....) * any underlying disease that may be incompatible with the management, discovery at the inclusion visit * cognitive problems making it impossible to assess the primary outcome measure * patients with a standardized rehabilitation program within 6 months prior to inclusion * impairment of comprehension or expression of the french language * patients participating in another clinical trial or participated in another clinical trial in the previous 3 months.

Keywords: scleroderma haq intensive care reeducation, readaptation
extracorporeal membrane oxygenation (ecmo) and coronavirus disease (covid) 19

Conditions: ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2; Acute Refractory Heart Failure Related to SARS-CoV 2

Summary: the role of ecmo in the treatment of patients with severe covid-19 (acute respiratory distress syndrome (ards) and/or acute refractory heart failure) is not yet known. the present study will aim to report the results of the ecmo management of the most severe forms of covid-19 through the first french ecmo registry.

the main objective of this study is to evaluate the hospital survival of covid-19 patients supported by venovenous or venoarterial ecmo in a multicenter registry. the secondary objectives are to describe the characteristics of covid-19 patients who have received ecmo support, to identify the risk factors associated with hospital mortality, to analyze the outcomes after ecmo weaning including survival at day 28 and day 90, and to analyze the utility of a circulatory support mobile unit in a severe pandemic inclusions are both prospective and retrospective in order to collect data over the whole pandemic

Eligibility criteria:
inclusion criteria: * all covid-19 patients, adults or children, * tested positive by rt-pcr for sars-cov2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest ct findings, * supported by venovenous or venoarterial ecmo exclusion criteria: * temporary legally protected adults over a set period or waiting for protection supervision, guardianship * patients or proxies who express their opposition to study participation

Keywords: ecmo covid-19 sars-cov2 ards myocarditis heart failure
effect of eeg-guided general anesthesia on cumulative dose of norepinephrine

Conditions: Hypotension

Summary: intraoperative hypotension is common in patients having non-cardiac surgery under general anesthesia and is associated with major postoperative complications including myocardial injury, aki, and death. intraoperative hypotension is also common in patients having vascular surgery. to treat intraoperative hypotension, vasopressors - such as norepinephrine - and fluids are used. however, high-dose vasopressor and excessive fluid therapy are also associated with postoperative complications. the depth of general anesthesia may be a modifiable cause of intraoperative hypotension. deep levels of general anesthesia may cause cardiovascular depression with intraoperative hypotension and higher vasopressor requirements. optimal depth of general anesthesia is defined as a state in which the patient is at low risk of recall of intraoperative events while maintaining blood pressure stability with minimal intervention. depth of anesthesia can be confirmed using clinical signs, the concentration of inhaled or intravenous anesthetics, or neuromonitoring such as processed electroencephalography (peeg). peeg presents an opportunity to monitor changes in human brain electrical activity and to help estimating the patients' level of (un)consciousness and the optimal depth of anesthesia. eeg-guided general anesthesia may thus decrease norepinephrine doses needed to treat intraoperative hypotension in patients having surgery.


Eligibility criteria:
we will include consenting patients ≥45 years scheduled for elective vascular surgery under general anesthesia if: * surgery is expected to last at least 60 min and * the estimated blood loss during surgery is less than 1000 ml and * intraarterial blood pressure monitoring (arterial catheter) is planned during surgery we will not include patients with previous transplantation of kidney, liver, heart, or lung and those who are septic (according to current sepsis-3 definition). and we will not include patients with american society of anesthesiologists' physical status v and vi, or pregnancy. we will exclude patients after randomization if they were treated with vasopressors others than norepinephrine during surgery. written informed consent will be obtained from all patients prior to study inclusion.
a behavioral intervention for reducing obesity

Conditions: Overweight; Obesity

Summary: this study will examine a contingency management (cm) intervention designed to provide incentives for losing weight versus participating in a manual-guided behavioral weight loss intervention alone. participants in the cm condition will earn the opportunity to win prizes by losing weight and completing activities that contribute to weight loss, such as keeping daily food and physical activity diaries, choosing healthy foods, exercising, and using other weight loss strategies. the investigators will determine if the cm improves weight loss relative to the usual care manual-guided intervention alone.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * body mass index in kg/m2 (bmi) between 30.0 and 39.9 * seated blood pressure of 100/60-140/90 mmhg * ability to speak english and read at the 6th grade level * willingness to be randomly assigned to one of two groups exclusion criteria: * any serious acute or chronic medical problems that may impact dietary or exercise regimens or impact weight loss * psychiatric exclusions

Keywords: overweight obesity contingency management